

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

A. Allum reports the following:

Employer: AstraZeneca; and Ownership Interest: AstraZeneca.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Alaster Allum

Manuscript ID: K360-2024-000349R1

Manuscript Title: Hyperkalemia-Related RAASi Reduction and Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining RAASi

Date of Completion: August 13, 2024

Disclosure Updated Date: May 21, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

D. Arroyo reports the following:

Employer: Hospital General Universitario Gregorio Marañón; Honoraria: Abbot, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Vifor, Eli-Lilly, Esteve, GSK, Menarini, Novo Nordisk, Otsuka; and Advisory or Leadership Role: Bayer.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: David A. Arroyo

Manuscript ID: K360-2024-000349R1

Manuscript Title: Hyperkalemia-Related RAASi Reduction and Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining RAASi

Date of Completion: July 7, 2024

Disclosure Updated Date: July 7, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

P. Breitbart reports the following:

Employer: University Heart Center Freiburg - Bad Krozingen; Consultancy: Speaker honoraria and consultancy fees from AstraZeneca, Bayer Vital, Bristol-Myers Squibb, Daiichi Sankyo, Novo Nordisk, Pfizer, and Sanofi Aventis.; Research Funding: Deutsche Herzstiftung e.V.; and Honoraria: Speaker honoraria and consultancy fees from AstraZeneca, Bayer Vital, Bristol-Myers Squibb, Daiichi Sankyo, Novo Nordisk, Pfizer, and Sanofi Aventis.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Philipp Breitbart

Manuscript ID: K360-2024-000349R1

Manuscript Title: Hyperkalemia-Related RAASi Reduction and Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining RAASi

Date of Completion: July 12, 2024

Disclosure Updated Date: July 12, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

T. Cars reports the following:

Employer: Sence Research AB; Consultancy: Thomas Cars is an employee and shareholder in Sence Research AB (Sence Research AB, a company in epidemiology and biostatistics with both healthcare authorities and private companies as clients); Ownership Interest: Sence Research AB; Ctatistics AB; Guard Therapeutics; Camurus; Research Funding: Thomas Cars is an employee and shareholder in Sence Research AB (Sence Research AB, a company in epidemiology and biostatistics with both healthcare authorities and private companies as clients); and Advisory or Leadership Role: CEO at Sence Research AB.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Thomas Cars

Manuscript ID: K360-2024-000349R1

Manuscript Title: Hyperkalemia-Related RAASi Reduction and Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining RAASi,

Date of Completion: July 9, 2024

Disclosure Updated Date: July 9, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

M. Fischereder reports the following:

Employer: Klinikum der LMU; Kuratorium fuer Dialyse und Nierentransplantation; Consultancy: Thermosome; Novartis; Sanofi; Ownership Interest: Novartis (share holder); Research Funding: Novartis, AstraZeneca; Honoraria: Astellas, AstraZeneca, Bayer Vital, Boehringer, Novartis, Pfizer, Sanofi, Vifor; Advisory or Leadership Role: Eurotransplant Kidney Advisory Committee (ETKAC, chair, not paid service); Speakers Bureau: Astellas, AstraZeneca, Bayer Vital, Boehringer, Novartis, Pfizer, Sanofi, Vifor; and Other Interests or Relationships: board member: KfH-Stiftung.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Michael Fischereder

Manuscript ID: K360-2024-000349R1

Manuscript Title: Hyperkalemia-Related RAASi Reduction and Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining RAASi

Date of Completion: August 16, 2024

Disclosure Updated Date: August 16, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

S. Franzén reports the following:

Employer: AstraZeneca; and Ownership Interest: AstraZeneca.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Stefan Franzén

Manuscript ID: K360-2024-000349R1

Manuscript Title: Hyperkalemia-Related RAASi Reduction and Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining RAASi

Date of Completion: August 5, 2024

Disclosure Updated Date: August 5, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

P. Kalra reports the following:

Employer: Portsmouth Hospitals University NHS Trust; Ownership Interest: Portsmouth Cardiac Associates; Hampshire Heart Clinic; Research Funding: Pharmacosmos; FIRE-1;; Honoraria: Amgen; Boehringer Ingelheim; Pharmacosmos; CSL Vifor; and Speakers Bureau: AstraZeneca; Bayer; Pharmacosmos; CSL Vifor; Amgen; Novartis; Pfizer.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Paul Kalra

Manuscript ID: K360-2024-000349R1

Manuscript Title: Hyperkalemia-Related RAASi Reduction and Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining RAASi

Date of Completion: August 14, 2024

Disclosure Updated Date: August 14, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

N. Kossack reports the following:

Employer: Wissenschaftliches Institut für Gesundheitsökonomie und Gesundheitssystemforschung

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Nils Kossack

Manuscript ID: K360-2024-000349R1

Manuscript Title: Hyperkalemia-Related RAASi Reduction and Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining RAASi

Date of Completion: August 10, 2024

Disclosure Updated Date: August 10, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

E. Lesén reports the following:

Employer: AstraZeneca; and Ownership Interest: AstraZeneca.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Eva Lesén

Manuscript ID: K360-2024-000349R1

Manuscript Title: Hyperkalemia-Related RAASi Reduction and Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining RAASi

Date of Completion: July 22, 2024

Disclosure Updated Date: July 22, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

I. Sanchez-Lazaro reports the following:

Employer: Hospital Vithas 9 de Octubre; and Speakers Bureau: Astra Zeneca; Novartis;

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Ignacio J Sanchez-Lazaro

Manuscript ID: K360-2024-000349R1

Manuscript Title: Hyperkalemia-Related RAASi Reduction and Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining RAASi,

Date of Completion: July 7, 2024

Disclosure Updated Date: July 7, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

M. Svensson reports the following:

Employer: Uppsala University, Uppsala, Sweden; and Honoraria: Amgen, AstraZeneca, Boehringer Ingelheim, GSK, NovoNordisk.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Maria K. Svensson

Manuscript ID: K360-2024-000349R1

Manuscript Title: Hyperkalemia-Related RAASi Reduction and Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining RAASi

Date of Completion: July 4, 2024

Disclosure Updated Date: May 11, 2024